RxDoctor Payments Data

Amy Keffer, MD

Internal Medicine · Sweeny, TXNPI 1467415133

Payments from drug & device makers

$2,689in general payments, 2019–2025

Across 150 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$736
  • AbbVie$558
  • Boehringer Ingelheim$282
  • Kowa Pharmaceuticals America, Inc.$281
  • Astellas Pharma US Inc$273
  • Amgen$154
  • plus $406 from 11 others

What the payments were for

  • Food & beverage$2,49193%
  • Education$1987%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,689 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$160,633
Medicare patients
426
Services billed
7,182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol129$108,454
JanuviaSitagliptin Phosphate83$91,764
OzempicSemaglutide77$91,497
EliquisApixaban50$53,082
Tresiba Flextouch U-200Insulin Degludec21$26,228
RybelsusSemaglutide23$23,247
XareltoRivaroxaban22$22,898
MyrbetriqMirabegron23$18,353
JardianceEmpagliflozin20$18,089
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$14,151
Tresiba Flextouch U-100Insulin Degludec11$13,879
Janumet XrSitagliptin Phos/Metformin Hcl20$13,605
Spiriva RespimatTiotropium Bromide15$12,752
Levothyroxine Sodium857$8,641
EntrestoSacubitril/Valsartan11$8,108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$736$129,420164 claims
Novo NordiskOzempic, Rybelsus$143$114,744100 claims
MerckJanuvia, Janumet Xr$13$105,369103 claims
PfizerEliquis$28$53,08250 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta$282$38,53250 claims
Johnson & JohnsonXarelto$21$22,89822 claims
Astellas Pharma US IncMyrbetriq$273$18,35323 claims
NovartisEntresto$13$8,10811 claims
AbbVieSynthroid$558$2,50379 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Sweeny

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →